CorMedix Inc. CRMD
4.82 USD +0.16 (+3.43%)
Regular-session close
4.85 +0.03 +0.62%
After hours · Nov 16, 6:57 PM ET
4.75 Day range 5.23
4.65 52-week range 13.02
- YTD
- -58.56%
- 1 year
- -57.12%
News
benzinga.com Deal Dispatch: Morgan Stanley Buys Vinyl Equity, Fox Completes Roku Acquisition, Children's Place Files for Chapter 11 Major M&A deals this week include: CorMedix buys Heron for $145M and Craveworthy Brands buys New England Authentic Eats.benzinga.com Oppenheimer Reiterates Outperform on Cormedix, Lowers Price Target to $13 Oppenheimer analyst Les Sulewski reiterates Cormedix (NASDAQ:CRMD) with a Outperform and lowers the price target from $15 to $13.
benzinga.com RBC Capital Maintains Outperform on Cormedix, Lowers Price Target to $14 RBC Capital analyst Leonid Timashev maintains Cormedix (NASDAQ:CRMD) with a Outperform and lowers the price target from $15 to $14.
zacks.com CRMD Stock Down 9% Despite Q3 Earnings and Revenues Beat Estimates CorMedix beats Q3 estimates, but DefenCath pricing pressure hurts sales. Rezzayo progress and the planned Heron acquisition shape its 2027 outlook.
seekingalpha.com CorMedix Inc. (CRMD) Q3 2026 Earnings Call Transcript CorMedix Inc. (CRMD) Q3 2026 Earnings Call Transcript
marketbeat.com What CorMedix (CRMD) Said on Its Q3 Earnings Call CorMedix NASDAQ: CRMD reported lower third-quarter revenue as its DefenCath product entered a new reimbursement period, while management outlined plans to acquire substantially all of Heron…
zacks.com CorMedix (CRMD) Reports Q3 Loss, Tops Revenue Estimates CorMedix (CRMD) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to earnings of $0.57 per share a year ago.
benzinga.com Cormedix Q3 2026 Earnings Call Transcript Cormedix (NASDAQ:CRMD) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…benzinga.com Cormedix Q3 EPS $(0.19) Misses $(0.10) Estimate, Sales $54.519M Beat $53.227M Estimate Cormedix (NASDAQ:CRMD) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.10) by 90 percent. This is a 133.33 percent decrease over earnings of $0.57…
benzinga.com Cormedix Affirms FY2026 Sales Guidance of $325.000M-$345.000M vs $337.061M Est Cormedix (NASDAQ:CRMD) affirms FY2026 sales outlook from $325.000 million-$345.000 million to $325.000 million-$345.000 million vs $337.061 million estimate.
globenewswire.com Cormedix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update ‒ Recently announced acquisition of assets of Heron Therapeutics – ‒ Q3 2026 consolidated revenue of $54.5 million ‒ ‒ Q3 2026 net loss of $14.7 million ; Adjusted EBITDA of $3.1 million ‒ ‒ Company…benzinga.com RBC Capital Maintains Outperform on Cormedix, Raises Price Target to $15 RBC Capital analyst Leonid Timashev maintains Cormedix (NASDAQ:CRMD) with a Outperform and raises the price target from $14 to $15.
zacks.com CRMD to Acquire HRTX Assets for $223M Upfront to Expand Portfolio CorMedix is set to acquire HRTX's commercial assets for $223 million upfront, adding four products, expanding its hospital reach and targeting significant cost synergies.
marketbeat.com CorMedix to Acquire Heron Assets, Adding Four Products and Targeting Up to $60 Million in Savings CorMedix NASDAQ: CRMD has agreed to acquire substantially all of Heron Therapeutics' assets, adding four commercial products and a development agreement to its portfolio of medicines used in…benzinga.com Needham Maintains Buy on Cormedix, Raises Price Target to $14 Needham analyst Serge Belanger maintains Cormedix (NASDAQ:CRMD) with a Buy and raises the price target from $12 to $14.
benzinga.com CorMedix Bolsters Hospital Pipeline via Heron Therapeutics Asset Deal CorMedix Therapeutics (NASDAQ:CRMD) on Monday said it will acquire substantially all assets and assume certain liabilities of Heron Therapeutics, Inc. (NASDAQ:HRTX) in an upfront transaction valued…
benzinga.com CorMedix Bolsters Hospital Pipeline via Heron Therapeutics Asset Deal CorMedix acquires Heron Therapeutics assets for $222.6 million upfront, adding four commercial hospital therapies to expand its acute care reach.benzinga.com CorMedix To Acquire Heron Therapeutics Assets For $145M Cash, Stock, And Potential Earn-Out Payments Adds four commercial-stage products — ZYNRELEF®, APONVIE®, CINVANTI® and SUSTOL® — to CorMedix's hospital- and acute-care-focused commercial platformUpfront consideration consisting of $145 million…
globenewswire.com CorMedix Therapeutics to Acquire Substantially All Assets of Heron Therapeutics, Expanding Its Portfolio of Products Used in Institutional Settings of Care Adds four commercial-stage products — ZYNRELEF ® , APONVIE ® , CINVANTI ® and SUSTOL ® — to CorMedix's hospital- and acute-care-focused commercial platform Upfront consideration consisting of $145…benzinga.com Needham Maintains Buy on Cormedix, Lowers Price Target to $12 Needham analyst Serge Belanger maintains Cormedix (NASDAQ:CRMD) with a Buy and lowers the price target from $15 to $12.
benzinga.com CorMedix Reaffirms FY26 Total Sales Guidance Of $325M-$345M; Anticipates That The DefenCath Add-On Will Decline Sequentially In Q2 2027, With A QoQ Increase In Q3 And/Or Q4 CorMedix announces unaudited cash and cash equivalents on hand as of September 30, 2026 of approximately $355 million. CorMedix reaffirms its August 2026 total revenue guidance of between $325…
benzinga.com CorMedix Therapeutics Says FDA Accepts sNDA Filing Seeking Approval Of REZZAYO For Prophylaxis Of Invasive Fungal Disease; PDUFA Target Action Date Set In Q1 2027 CorMedix Therapeutics (NASDAQ:CRMD) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the supplemental New Drug Application (sNDA) seeking approval of REZZAYO®…
